The effect of MELatOnin on depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: Protocol for a randomised, placebo-controlled, double-blinded trial

BMJ Open

Volumn 2, Issue 1, 2012, Pages

  Hansen, Melissa Voigt ^a   Madsen, Michael Tvilling ^a   Hageman, Ida ^a   Rasmussen, Lars Simon ^a   Bokmand, Susanne ^a   Rosenberg, Jacob ^a   Gögenur, Ismail ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; PER3 PROTEIN; PLACEBO; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG;

ACTIMETRY; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG INDUCED HEADACHE; DYSPEPSIA; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NAUSEA; NEUROPSYCHOLOGICAL TEST; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP QUALITY; SLEEP WAKING CYCLE; SOMNOLENCE; VISUAL ANALOG SCALE;

EID: 84859031573     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000647     Document Type: Article

References (103)

1. http://globocan. iarc.fr/factsheets/cancers/breast.asp (accessed Nov. 2011).
2. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36. (Pubitemid 32166444)
3. http://www.sst.dk/publ/Publ2009/DOKU/cancerreg/cancerregisteret-2008.pdf (accessed Nov. 2011).
4. http://www.sst.dk/publ/Publ2010/DOKU/Sygehusbaseret Overlevelse/ SygehuspatientersOverlevelse1997-2008.pdf (accessed Nov. 2011).
5. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-030975.pdf (accessed Nov. 2011).
6. Fann JR, Thomas-Rich AM, Katon WJ, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 2008;30:112-26. (Pubitemid 351248974)
7. Burgess C, Cornelius V, Love S, et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005;330:702-5. (Pubitemid 40470014)
8. Otte JL, Carpenter JS, Russell KM, et al. Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors. J Pain Symptom Manage 2010;39:535-47.
9. Debess J, Riis JO, Pedersen L, et al. Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. Acta Oncol 2009;48:532-40.
10. Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001;24:583-90. (Pubitemid 32660384)
11. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004;32:57-71.
12. Schou I, Ekeberg O, Sandvik L, et al. Multiple predictors of healthrelated quality of life in early stage breast cancer. Data from a year follow-up study compared with the general population. Qual Life Res 2005;14:1813-23. (Pubitemid 41279604)
13. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 1998;351:857-61.
14. Olsen LR, Mortensen EL, Bech P. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr Scand 2004;109:96-103. (Pubitemid 38186820)
15. Bech P, Rasmussen NA, Olsen LR, et al. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord 2001;66:159-64. (Pubitemid 32907521)
16. Olsen LR, Jensen DV, Noerholm V, et al. The internal and external validity of the Major Depression Inventory in measuring severity of depressive states. Psychol Med 2003;33:351-6. (Pubitemid 36221467)
17. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005;9:11-24. (Pubitemid 40092915)
18. Acil M, Basgul E, Celiker V, et al. Perioperative effects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance. Eur J Anaesthesiol 2004;21:553-7. (Pubitemid 38987989)
19. Naguib M, Samarkandi AH. Premedication with melatonin: a doubleblind, placebo-controlled comparison with midazolam. Br J Anaesth 1999;82:875-80. (Pubitemid 29245617)
20. Caumo W, Torres F, Moreira NL Jr, et al. The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 2007;105:1263-71. (Pubitemid 350303928)
21. Srinivasan V, Pandi-Perumal SR, Spence DW, et al. Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull 2010;81:362-71.
22. Cagnacci A, Cannoletta M, Renzi A, et al. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005;18:1614-18. (Pubitemid 41814684)
23. Kitajima T, Kanbayashi T, Saitoh Y, et al. The effects of oral melatonin on the autonomic function in healthy subjects. Psychiatry Clin Neurosci 2001;55:299-300. (Pubitemid 32578389)
24. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001;10:467-76. (Pubitemid 32186144)
25. Vijayalaxmi B, Thomas CR Jr, Reiter RJ, et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20:2575-601. (Pubitemid 34525746)
26. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004;37:213-14. (Pubitemid 39274120)
27. Grant SG, Melan MA, Latimer JJ, et al. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 2009;11:e5.
28. Bellipanni G, Di MF, Blasi F, et al. Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann N y Acad Sci 2005;1057:393-402. (Pubitemid 43211649)
29. Kopp C, Vogel E, Rettori MC, et al. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol 1999;10:73-83. (Pubitemid 29106290)
30. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621-31.
31. Serfaty MA, Osborne D, Buszewicz MJ, et al. A randomized doubleblind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 2010;25:132-42.
32. G. Spadoni, A. Bedini, S. Rivara, et al. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. Published Online First: 15 October 2010. doi: 10.1111/j.1755-5949.2010.00197.x
33. Garzon C, Guerrero JM, Aramburu O, et al. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebocontrolled study. Aging Clin Exp Res 2009;21:38-42.
34. Rahman SA, Kayumov L, Shapiro CM. Antidepressant action of melatonin in the treatment of Delayed Sleep Phase Syndrome. Sleep Med 2010;11:131-6.
35. Srinivasan V, Pandi-Perumal SR, Trakht I, et al. Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res 2009;165:201-14.
36. Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res 2007;43:404-9. (Pubitemid 47512272)
37. Ram E, Vishne TH, Weinstein T, et al. General anesthesia for surgery influences melatonin and cortisol levels. World J Surg 2005;29:826-9. (Pubitemid 41800709)
38. Karkela J, Vakkuri O, Kaukinen S, et al. The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiol Scand 2002;46:30-6. (Pubitemid 34208233)
39. Gogenur I, Middleton B, Kristiansen VB, et al. Disturbances in melatonin and core body temperature circadian rhythms after minimal invasive surgery. Acta Anaesthesiol Scand 2007;51:1099-106. (Pubitemid 47246920)
40. Megdal SP, Kroenke CH, Laden F, et al. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 2005;41:2023-32. (Pubitemid 41557687)
41. Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab 1977;45:768-74. (Pubitemid 8212527)
42. Nickkholgh A, Schneider H, Sobirey M, et al. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res 2011;50:381-8.
43. Seabra ML, Bignotto M, Pinto LR Jr, et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000;29:193-200.
44. Jahnke G, Marr M, Myers C, et al. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999;50:271-9. (Pubitemid 29407090)
45. Barchas J, Da Costa F, Spector S. Acute pharmacology of melatonin. Nature 1967;214:919-20.
46. Shaw KM, Stern GM, Sandler M. Melatonin and parkinsonism. Lancet 1973;1:271.
47. Zhdanova IV, Wurtman RJ, Morabito C, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996;19:423-31. (Pubitemid 26256757)
48. Gitto E, Romeo C, Reiter RJ, et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004;39:184-9. (Pubitemid 38146434)
49. Gitto E, Karbownik M, Reiter RJ, et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001;50:756-60. (Pubitemid 33121647)
50. Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006;332:385-93.
51. Dijk DJ, Archer SN. PERIOD3, circadian phenotypes, and sleep homeostasis. Sleep Med Rev 2010;14:151-60.
52. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep 2003;26:413-15. (Pubitemid 39610658)
53. Johansson C, Willeit M, Smedh C, et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 2003;28:734-9.
54. Viola AU, Archer SN, James LM, et al. PER3 polymorphism predicts sleep structure and waking performance. Curr Biol 2007;17:613-18. (Pubitemid 46497792)
55. Nievergelt CM, Kripke DF, Barrett TB, et al. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2006;141B:234-41.
56. Artioli P, Lorenzi C, Pirovano A, et al. How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. Eur Neuropsychopharmacol 2007;17:587-94. (Pubitemid 47068935)
57. Groeger JA, Viola AU, Lo JC, et al. Early morning executive functioning during sleep deprivation is compromised by a PERIOD3 polymorphism. Sleep 2008;31:1159-67.
58. Zhu Y, Brown HN, Zhang Y, et al. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 2005;14:268-70. (Pubitemid 40165313)
59. Ancoli-Israel S, Cole R, Alessi C, et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003;26:342-92. (Pubitemid 39610685)
60. Bisgaard T, Kjaersgaard M, Bernhard A, et al. Computerized monitoring of physical activity and sleep in postoperative abdominal surgery patients. J Clin Monit Comput 1999;15:1-8. (Pubitemid 29231661)
61. Cole RJ, Kripke DF, Gruen W, et al. Automatic sleep/wake identification from wrist activity. Sleep 1992;15:461-9.
62. Berger AM, Wielgus K, Hertzog M, et al. Patterns of circadian activity rhythms and their relationships with fatigue and anxiety/depression in women treated with breast cancer adjuvant chemotherapy. Support Care Cancer 2010;18:105-14.
63. Wright CE, Bovbjerg DH, Montgomery GH, et al. Disrupted sleep the night before breast surgery is associated with increased postoperative pain. J Pain Symptom Manage 2009;37:352-62.
64. Ancoli-Israel S, Liu L, Marler MR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 2006;14:201-9. (Pubitemid 43247923)
65. Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002;10:329-36. (Pubitemid 36056288)
66. Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci 1990;52:29-37.
67. Caplette-Gingras A, Savard J. Depression in women with metastatic breast cancer: a review of the literature. Palliat Support Care 2008;6:377-87.
68. Somerset W, Stout SC, Miller AH, et al. Breast cancer and depression. Oncology 2004;18:1021-34.
69. Hjerl K, Andersen EW, Keiding N, et al. Depression as a prognostic factor for breast cancer mortality. Psychosomatics 2003;44:24-30. (Pubitemid 36050569)
70. Watson M, Haviland JS, Greer S, et al. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 1999;354:1331-6. (Pubitemid 29481628)
71. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a metaanalysis. Cancer 2009;115:5349-61.
72. Abrams TE, Vaughan-Sarrazin M, Rosenthal GE. Influence of psychiatric comorbidity on surgical mortality. Arch Surg 2010;145:947-53.
73. Bui QU, Ostir GV, Kuo YF, et al. Relationship of depression to patient satisfaction: findings from the barriers to breast cancer study. Breast Cancer Res Treat 2005;89:23-8. (Pubitemid 40228444)
74. Colleoni M, Mandala M, Peruzzotti G, et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 2000;356:1326-7.
75. Di Matteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7. (Pubitemid 30482715)
76. Hartl K, Schennach R, Muller M, et al. Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients. Psychosomatics 2010;51:112-23.
77. Giese-Davis J, Collie K, Rancourt KM, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 2011;29:413-20.
78. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 2008;112:197-201.
79. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001;70:1-10. (Pubitemid 33105097)
80. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005;89:243-9. (Pubitemid 43293071)
81. van HK, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 1996;169:440-3.
82. Musselman DL, Somerset WI, Guo Y, et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 2006;67:288-96. (Pubitemid 43357477)
83. Grassi L, Biancosino B, Marmai L, et al. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry 2004;65:515-20.
84. Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003;21:1937-43. (Pubitemid 46606381)
85. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:4635-41. (Pubitemid 46594038)
86. Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncology 1999;13:1293-301.
87. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693.
88. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688-97.
89. Davidson JR, MacLean AW, Brundage MD, et al. Sleep disturbance in cancer patients. Soc Sci Med 2002;54:1309-21. (Pubitemid 34240048)
90. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001;19:895-908. (Pubitemid 32119105)
91. Fortner BV, Stepanski EJ, Wang SC, et al. Sleep and quality of life in breast cancer patients. J Pain Symptom Manage 2002;24:471-80. (Pubitemid 36120423)
92. Koopman C, Nouriani B, Erickson V, et al. Sleep disturbances in women with metastatic breast cancer. Breast J 2002;8:362-70. (Pubitemid 35334651)
93. Dow KH, Ferrell BR, Leigh S, et al. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat 1996;39:261-73. (Pubitemid 26278941)
94. Morin CM, Ware JC. Sleep and psychopathology. Appl Prev Psychol 1996;5:211-24.
95. Benca RM, Okawa M, Uchiyama M, et al. Sleep and mood disorders. Sleep Med Rev 1997;1:45-56. (Pubitemid 127674869)
96. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-18. (Pubitemid 26124560)
97. Livingston G, Blizard B, Mann A. Does sleep disturbance predict depression in elderly people? A study in inner London. Br J Gen Pract 1993;43:445-8. (Pubitemid 23342753)
98. Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 2001;10:245-55. (Pubitemid 33699428)
99. Palesh OG, Collie K, Batiuchok D, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol 2007;75:37-44. (Pubitemid 46415652)
100. Wefel JS, Lenzi R, Theriault R, et al. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004;101:466-75.
101. Jim HS, Donovan KA, Small BJ, et al. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 2009;115:1776-83.
102. Manda K, Reiter RJ. Melatonin maintains adult hippocampal neurogenesis and cognitive functions after irradiation. Prog Neurobiol 2010;90:60-8.
103. Sharma AK, Mehta AK, Rathor N, et al. Melatonin attenuates cognitive dysfunction and reduces neural oxidative stress induced by phosphamidon. Fundam Clin Pharmacol. Published Online First: 26 July 2011. doi: 10.1111/j.1472-8206. 2011.00977.x